REPEAT – Pure Extracts Collaborates with Dr. Alexander MacGregor on Cannabis and Mushroom Formulations

VANCOUVER, British Columbia, Dec. 02, 2020 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushroom sector, is pleased to provide an introduction to Dr. Alexander MacGregor, a key scientific advisor to the Company.

Pure Extracts and Dr. MacGregor are collaborating on the development of CBD infused mushroom wellness products and are researching the optimum extraction methodologies for psilocybin in order to prepare the Company to enter the psychedelic mushroom extraction space.

Dr. MacGregor is the Dean of Faculty, distinguished Professor of Biopharmaceutics and current President of the Toronto Institute of Pharmaceutical Technology (TIPT^®) – North America’s premier post-graduate institute of pharmaceutical sciences, technology and research. He is also the CEO of TIPT’s parent company, Transpharm Canada Inc., which has a Health Canada Drug Establishment License, a Cannabis Drug License and a Dealer’s License issued under the Controlled Drugs and Substances Act (CDSA). Transpharm Canada conducts cannabis testing, clinical trials, drug development and is licensed to possess psychedelic drug compounds.

Dr. MacGregor is recognized as a pharmaceutical science inventor and expert in pharmaceutical technology and novel drug delivery systems. He is a recipient of several global patents in the field of medical treatments and pharmaceutical drug delivery technologies most notably from Canada, US, Australia, Europe, Latin America, China, India and Japan. His inventions have led to groundbreaking therapeutic drugs for the treatment of cancer, management of diabetes, systemic infections, and post-operative pain.

An expert in translating pharmaceutical knowledge into sustainable businesses, Dr. MacGregor was a consultant to multi-national pharmaceutical companies such as GlaxoSmithKline, Valeant, Teva, Patheon, Sun Pharma and Beijing Double-Crane Pharma. He was appointed by the Government of China as an International Advisor in the field of pharmaceutical technology and research through a nomination proffered by the City of Beijing and Beijing Double-Crane Pharmaceutical Co. (China’s third largest pharmaceutical company).

He is the author and co-author of several articles and manuscripts in the field of pharmaceutical science and technology, a founding member and Chair of the Canadian Association of Pharmaceutical Technologists (CapTech) and the founding member and past-Chair of the Toronto Pharmaceutical Ethics Committee for research in humans. He is a member of several scientific associations such as the prestigious Control Release Society (CRS), Canadian Society of Pharmaceutical Sciences (CSPS) and the American Association of Pharmaceutical Sciences (AAPS).

Dr. MacGregor received an honours degree (Magna Cum Laude-BSc) in Medical Biochemistry and Doctor of Philosophy (Ph.D.) in Clinical Pharmacology from the University of Wales and the Royal Post-Graduate Medical School London, UK.

About Pure Extracts (CSE: PULL) (XFRA: A2QJAJ)
The Company features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. On September 25, 2020, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act and the Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020. Find out more at https://pureextractscorp.com/.

For further information please contact Empire Communications Group at (604) 343-2724.

ON BEHALF OF THE BOARD
“Ben Nikolaevsky”
Ben Nikolaevsky
CEO and Director

The CSE has neither approved nor disapproved the contents of this press release.

This news release contains forward-looking statements relating to the future operations of Pure Extracts, and the other statements are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of Pure Extracts include risks detailed from time to time in the filings made by Pure Extracts under securities regulations.